12th Dec 2014 07:00
12 December 2014
Immunodiagnostic Systems Holdings plc.
Launch of Fully Automated 1,25-Dihydroxy Vitamin D Assay
Immunodiagnostic Systems Holdings plc (IDS), a leading solution provider to the clinical laboratory diagnostic market, today announced it has received European CE Mark declaration for the IDS-iSYS 1,25 VitDXp assay - a fully automated assay for use with the IDS-iSYS Multi-Discipline Automated System.
The IDS-iSYS 1,25 VitDXp assay assesses 1,25-Dihydroxy Vitamin D status and deficiencies associated with renal disease and disorders of calcium metabolism. Market value of 1,25-Dihyroxy Vitamin D testing is estimated to be circa £15 million per annum in Europe.
Patrik Dahlen, CEO of IDS, said: "Continuing IDS's heritage and expertise in endocrinology and Vitamin D testing, the IDS-iSYS 1,25 VitDXp uses a proven and trusted technology to fully automate purification and quantification of 1,25-Dihydroxy Vitamin D. The excellent assay stability, walk away convenience and ease-of-use provides laboratories significant workflow and productivity advantages."
Available now, IDS offers laboratories evaluating calcium metabolism and Vitamin D deficiencies a comprehensive, fully automated solution.
For further information:
Immunodiagnostic Systems Holdings plc | Tel : +44 (0)191 5190660 |
Patrik Dahlen, CEO | |
Chris Yates, CFO | |
Peel Hunt LLP | Tel : +44 (0)207 418 8900 |
James Steel / Jock Maxwell Macdonald | |
FTI Consulting | Tel : +44 (0)203 727 1000 |
Ben Atwell / Simon Conway / Mo Noonan |
About Immunodiagnostic Systems Holdings PLC
The Group's vision is to be a leading solution provider to the clinical laboratory diagnostic market. IDS's strategy is focused on developing, internally and through partnership, its automated assay menu for its proprietary automated immunoassay analyser, the IDS-iSYS system. Internally the Group is focused on developing an endocrinology excellence menu and externally IDS works with partners to develop assay panels in complementary indication fields. The Group sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician office laboratories. IDS has field sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.
Related Shares:
IDH.L